High dose ultra short Primaquine

Phase 3Small molecule

MMenzies School of Health Research

High dose ultra short Primaquine is one of 21 small molecule programs targeting Malaria. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MalariaActive, not recruiting

MalariaPhase 3

Active, not recruiting

Competition

Competitive Landscape

479 competitors in Malaria

#DrugCompanyPhaseTrials

High dose ultra short Primaquine

MMenzies School of Health Research

Phase 3

1 2

Biltricide

Bayer

Preclinical

1 3

Stelara

Johnson & Johnson

Preclinical

—4

Hydroxychloroquine Sulfate

Novartis

Preclinical

—5

Iron

WWatson Pharmaceuticals

Preclinical

1 6

IV LBH589

Novartis

Preclinical

1 7

Mefloquine Plus Artesunate

Medicines for Malaria Venture

Preclinical

1 8

IV Ceftriaxone

RRESnTEC, Institute of Research

Preclinical

1 9

RTS,S/AS01E

GSK

Preclinical

4 10

Malarone

Medicines for Malaria Venture

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 3Not yet recruiting

Malaria

NCT07468526

Clinical

Trials by Indication[1]

Malaria1 trial

An Ultra-short Course of Primaquine for the Radical Cure of Vivax Malaria

Not yet recruiting·MMenzies School of Health Research·Phase 3·NCT07468526·1,019 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for High dose ultra short Primaquine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — High dose ultra short Primaquine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for High dose ultra short Primaquine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Menzies School of Health Research company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMenzies School of Health Research

High dose ultra short Primaquine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Malaria1 trial

References

Drug Info

Quick Facts

Related News